Exonuclease-deficient Extracts
Exonuclease-deficient Extracts - Related Videos
08:11
Cell-Free Protein Synthesis from Exonuclease-Deficient Cellular Extracts Utilizing Linear DNA Templates
0 Views •
Cited by 2 •
2022
Presented here is a protocol for the preparation and buffer calibration of cell extracts from exonuclease V knockout strains of Escherichia coli BL21 Rosetta2 (ΔrecBCD and ΔrecB). This is a fast, easy, and direct approach for expression in cell-free protein synthesis systems using linear DNA templates.
06:10
A Fluorescence-based Exonuclease Assay to Characterize DmWRNexo, Orthologue of Human Progeroid WRN Exonuclease, and Its Application to Other Nucleases
0 Views •
Cited by 4 •
2013
Exonucleases play critical roles in ensuring genome stability. Loss of WRN exonuclease function results in premature aging. Studying substrates and other requirements of the nuclease in vitro can help elucidate its role in vivo. Here we demonstrate a rapid and reproducible fluorescence-based assay to measure its nuclease activity.
01:30
Capital Deficiency in Liquidation: I
0 Views •
2026
During the liquidation of a partnership, a capital deficiency occurs when a partner’s capital account becomes negative after accounting for allocated losses and the payment of liabilities. Resolving such deficiencies is a critical step before the remaining assets can be distributed. However, complications arise when a partner is unable or unwilling to contribute additional funds to eliminate their deficiency.In cases where a partner cannot satisfy their capital deficiency, the loss must be...
01:25
Capital Deficiency in Liquidation: II
0 Views •
2026
A capital deficiency occurs when a partner's capital account has a debit balance during partnership liquidation. It may result from operating losses, excessive drawings, or losses from the sale of partnership assets. During liquidation, noncash assets are sold, liabilities are paid, gains or losses are allocated to the partners, and the remaining cash is distributed based on the partners' capital balances.Example: Ace Company decides to liquidate because it is nearing bankruptcy. Noncash assets...
01:30
No Capital Deficiency in Liquidation
0 Views •
2026
In accounting, liquidation without capital deficiency is a structured process that enables a partnership to dissolve equitably when partners possess sufficient capital to cover all liabilities and allocated losses. This condition ensures that no partner is required to contribute additional funds to the partnership, streamlining the dissolution procedure.The liquidation process begins with conversion of noncash assets into cash. When these assets are sold, any difference between the sale price...
FAQs
The key advantage comes from limiting degradation at exposed molecular ends, where exonuclease activity can progressively shorten linear DNA or other nucleic acid substrates. Preserving those templates allows the extract’s transcription, translation, and metabolic activities to continue using more intact input, supporting more consistent in vitro reactions over time.
An effective preparation must balance protection with retained biochemical activity. Reducing the relevant exonucleases improves template stability, but the extract still needs the functions that drive transcription, translation, and metabolism. This balance matters because protection alone would not support productive cell-free synthesis or broader synthetic biology reactions.
Compared with conventional extracts, exonuclease-deficient extracts are particularly useful when a reaction depends on linear DNA designs that would otherwise be vulnerable to progressive end-directed degradation. The distinction is practical rather than merely compositional: greater template persistence can make linear constructs more suitable for prototyping and other in vitro engineering workflows.
In cell-free protein synthesis, improved template stability helps preserve the DNA instructions used by the extract’s transcription and translation machinery. For genetic circuit prototyping, this protection can support testing of linear DNA designs without relying exclusively on more degradation-resistant formats. The result is a more reliable platform for evaluating engineered genetic functions in vitro.
Improved template stability can extend the duration of a cell-free reaction and increase the amount of product generated during that period. These effects are linked to continued availability of intact nucleic acid templates rather than to a separate catalytic function. Researchers can therefore use the extracts when reaction persistence and output are important performance considerations.
The extracts are relevant to biosensor development and the assembly of synthetic biological systems, in addition to protein synthesis and genetic circuit testing. In these settings, maintaining usable nucleic acid templates supports the operation or evaluation of engineered components in vitro. Their value is greatest when template degradation would otherwise limit the reliability or duration of the reaction.